Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/16/25
End: 11/30/26
Due: 11/30/27
Phase: N/A
Priority: Normal
Start: 12/11/14
End: 03/31/19
Due: 03/31/20
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients | NCT06923891 | Vanguard Research Group | user2@example.com | None | 2025-04-16 | 2026-11-30 | 2027-11-30 | - | - | 2025-07-14 |
| Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics | NCT02360319 | Vanguard Research Group | user2@example.com | None | 2014-12-11 | 2019-03-31 | 2020-03-31 | - | - | 2025-07-14 |